Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Компания Amgen Inc. демонстрирует сильные финансовые показатели с высокими значениями ROE (96.19) и ROA (7.80), значительно превышающими медианы отрасли, что указывает на эффективное использование капитала. Тем не менее, мультипликаторы P/E (26.62) и P/B (19.30) существенно выше медианных значений, что может свидетельствовать о переоцененности акций. Уровень долга (debt/equity 5.45) также вызывает опасения, так как превышает медиану отрасли, что увеличивает риски для инвесторов. При этом, компания показывает стабильный рост выручки и чистой прибыли, что положительно сказывается на оценке. Дивидендная доходность в 0.68% остается относительно низкой, однако стабильна. В целом, сильные стороны компании включают высокий уровень прибыли и управление активами, в то время как высокие мультипликаторы и долговая нагрузка могут ограничивать рост акций в будущем. Эти факторы создают смешанную картину для оценки, что требует осторожного подхода к инвестициям.

Amgen Inc.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $620.6 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 434,800,108 to 440,350,108). Among the largest underlying components of SPYG, in trading today Uber Technologies Inc (Symbol: UBER) is trading flat, Morgan Stanley (Symbol: MS) is down about 1.2%, and Amgen Inc (Symbol: AMGN) is lower by about 1.7%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $79.75 per share, with $112.98 as the 52 week high point — that compares with a last trade of $111.66. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Project your dividend income with confidence: Income Calendar tracks your income portfolio like a personal assistant.
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Joel Greenblatt Stock Picks
Funds Holding NWL
Materials Stocks Hedge Funds Are Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

SPYG, UBER, MS, AMGN: ETF Inflow Alert

AstraZeneca AZN reported first-quarter 2026 core earnings of $2.58 per share, which marginally beat the Zacks Consensus Estimate of $2.57. The bottom line rose 4% year over year on a reported basis and 5% at constant exchange rate (CER).
Total revenues of $15.29 billion rose 13% on a reported basis and 8% at CER, beating the Zacks Consensus Estimate of $14.96 billion.
All growth rates mentioned below are on a year-over-year basis and at CER.
AZN shares began trading on the NYSE on Feb. 2. Earlier, in the United States, investors traded AstraZeneca through a different structure called American Depositary Shares (ADS) on Nasdaq.
AZN’s Product Sales & Alliance Revenues
Product sales increased 7% to $14.39 billion.
Alliance revenues rose 26% to $825 million, driven by continued revenue growth from partnered medicines. Alliance revenues include royalties and profit share from partnered medicines, such as Enhertu and Tezspire, in geographies where its partner books product sales.
AstraZeneca’s Key Oncology Drugs Drive Growth
Here, we have discussed AstraZeneca’s total drug revenues by including Alliance and Collaboration revenues in each revenue figure.
In Oncology, Tagrisso recorded revenues of $1.83 billion, up 5% year over year, driven by strong demand across all indications and regions, partly offset by tender outcomes and phasing in Emerging Markets, and seasonal variability in Japan ahead of fiscal year-end. Tagrisso sales missed the Zacks Consensus Estimate of $1.86 billion.
Lynparza's total revenues rose 2% to $781 million, driven by increased market share/demand growth for all approved indications and continued uptake in breast and prostate cancers across Europe. The growth was partially offset by the impact of generic launches in China and by VBP-associated stock compensation costs. The drug’s sales, however, beat the Zacks Consensus Estimate of $755 million.
AstraZeneca markets Lynparza in partnership with Merck MRK. During the quarter, the company did not record any milestone payment from partner Merck related to the drug.
Imfinzi generated sales of $1.69 billion in the quarter, up 30%, driven by strong demand growth across all regions from existing indications and new launches. Imfinzi sales, however, missed the Zacks Consensus Estimate of $1.79 billion. Sales of Calquence rose 17% to $923 million in the quarter. New breast cancer drug Truqap recorded $198 million in revenues in the first quarter of 2026, up 47% year over year on achieving peak share in second-line biomarker-altered metastatic breast cancer.
Newly approved drug Datroway, for which it has a partnership with Daiichi Sankyo, recorded revenues of $43 million in the quarter compared with $40 million in the previous quarter.
Year to date, the stock has risen 1.5% against the industry’s 1.6% decline.
Image Source: Zacks Investment Research
AZN’s CVRM Segment Performance
In CVRM, Farxiga recorded product sales of $2.24 billion, down 3%, despite continued demand growth across chronic kidney disease and heart failure indications and SGLT2 class growth. However, sales were affected by generic competition in some markets like China, Japan and the United Kingdom and the VBP impact in China. Farxiga sales, however, beat the Zacks Consensus Estimate of $2.08 billion.
Brilinta/Brilique sales totaled $105 million in the reported quarter, down 67%, due to the generic launch in Europe and the United States.
Wainua recorded $51 million in product sales during the quarter, up 28% year over year, driven by strong demand growth in transthyretin amyloid polyneuropathy.
AZN’s R&I Segment Performance
In R&I, Symbicort sales declined 1% to $747 million as demand for an authorized generic was offset by price pressures in the United States and generic erosion in Europe. The drug’s sales, however, beat the Zacks Consensus Estimate of $734 million.
Fasenra recorded sales of $483 million in the quarter, up 11% year over year, driven by strong demand growth and market share gains. The recent launch for the EGPA indication also benefited sales in some countries. The drug’s sales beat the Zacks Consensus Estimate of $478 million.
Breztri recorded sales of $353 million, up 13% year over year, driven by a consistent share increase in a growing market.
Pulmicort sales declined 11% to $149 million due to continued generic competition in Emerging Markets.
New product Airsupra generated $37 million in product sales in the quarter, up 31% year over year. The product’s U.S. launch momentum remains strong.
New lupus drug, Saphnelo, recorded sales of $171 million, up 24% year over year, driven by demand growth in the U.S. market and ongoing launches in Europe and Established RoW.
Tezspire recorded total revenues of $303 million, up 34% year over year, driven by demand growth and launch uptake in multiple markets. AstraZeneca has a partnership with Amgen AMGN for Tezspire. Amgen records product sales in the United States, and AstraZeneca records its share of U.S. gross profits as Alliance revenues. AstraZeneca books product sales in markets outside the United States.
AstraZeneca PLC Price, Consensus and EPS Surprise
AZN’s Rare Disease, V&I and Other Segment
In the Rare Disease portfolio, Soliris sales fell 14% to $389 million due to conversion to Ultomiris and biosimilar erosion in Europe and the United States.
Ultomiris revenues amounted to $1.27 billion, up 18%, driven by demand growth across indications, geographic expansions in new markets and continued conversion from Soliris.
In Other Medicines, sales of Nexium declined 9% to $253 million.
In V&I Therapies, AstraZeneca recorded $116 million in revenues from Beyfortus, including alliance revenues received from partner Sanofi SNY and sales of the manufactured Beyfortus product to Sanofi. Revenues increased 3% year over year.
AZN Reiterates 2026 Guidance
AstraZeneca reconfirmed its financial guidance for 2026.
It continues to expect total revenues to grow by a mid-to-high single-digit percentage at CER.
Core EPS is expected to increase by a low double-digit percentage at CER.
AZN’s Zacks Rank
Currently, AstraZeneca has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AZN Q1 Earnings and Sales Beat, Key Drugs Offset Generic Pressure

(RTTNews) - It takes 10-15 years and billions of dollars for a pharma company to bring a drug to the market. Now imagine that after years of effort, time, and investment, a company is forced to pull the drug from the market because the data used to secure approval was manipulated.
That is the situation unfolding with ChemoCentryx's Tavneos, which received FDA approval in October 2021, for the adjunctive treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare autoimmune diseases.
ChemoCentryx Inc., the developer of Tavneos, was acquired by Amgen Inc. (AMGN) in August 2022 for $4 billion in cash. The deal was then seen as a strategic move to strengthen Amgen's long-standing leadership in inflammation and nephrology, with Tavneos representing a first-in-class, transformative treatment for ANCA-associated vasculitis.
Now, the Center for Drug Evaluation and Research (CDER) has determined that the results from the pivotal clinical study may have been manipulated to make Tavneos appear effective, when the original analysis did not support that conclusion. As a result, the agency now says there is no valid demonstration of Tavneos' efficacy for its approved use.
The CDER has proposed withdrawing the drug from the market and has issued a notice of opportunity for a hearing (NOOH) to the application holder of Tavneos, i.e., ChemoCentryx, which is now a subsidiary of Amgen (AMGN).
Adding to the concerns, the FDA in March of this year identified serious postmarketing safety issues, including vanishing bile duct syndrome (VBDS), in patients taking Tavneos and has been alerting patients and health care professionals. VBDS is characterized by progressive destruction and disappearance of the bile ducts in the liver, and this condition can slow or stop the flow of bile and may lead to permanent liver damage.
Tavneos will continue to remain on the market until Amgen/ChemoCentryx decide to pull the plug or the FDA Commissioner steps in to require its removal. If a hearing is sought, the FDA Commissioner will determine whether to hold a public hearing and, following such a hearing, decide whether to ultimately take the drug off the market.
Net sales of Tavneos were $459 million in full-year 2025, compared to $283 million in 2024. The drug is approved in multiple markets, including the United States, Australia, the European Union, Canada, Japan, the United Kingdom, and Switzerland, among others.
AMGN is currently trading at $343.14, up 0.88%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Did Amgen's Subsidiary Manipulate Data To Secure Tavneos Approval?

At Holdings Channel, we have reviewed the latest batch of the 72 most recent 13F filings for the 03/31/2026 reporting period, and noticed that Amgen Inc (Symbol: AMGN) was held by 35 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen.
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in AMGN positions, for this latest batch of 13F filers:
Fund
New Position?
Change In Share Count
Change In Market Value ($ in 1000's)
Aggregate Change:
-7,104
+$16,259
In terms of shares owned, we count 15 of the above funds having increased existing AMGN positions from 12/31/2025 to 03/31/2026, with 13 having decreased their positions and 3 new positions.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the AMGN share count in the aggregate among all of the funds which held AMGN at the 03/31/2026 reporting period (out of the 2,423 we looked at in total). We then compared that number to the sum total of AMGN shares those same funds held back at the 12/31/2025 period, to see how the aggregate share count held by hedge funds has moved for AMGN. We found that between these two periods, funds increased their holdings by 907,614 shares in the aggregate, from 13,674,492 up to 14,582,106 for a share count increase of approximately 6.64%. The overall top three funds holding AMGN on 03/31/2026 were:
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Amgen Inc (Symbol: AMGN).
Also see:

See Which Recent 13F Filers Hold AMGN

Friday, April 24, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Caterpillar Inc. (CAT), Texas Instruments Inc. (TXN) and The Boeing Co. (BA), as well as two micro-cap stocks Kewaunee Scientific Corp. (KEQU) and Vaso Corp. (VASO). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Earnings Season, Middle East Truce Talks, Gain Favor
Caterpillar’s shares have outperformed the Zacks Manufacturing - Construction and Mining industry over the past six months (+60.5% vs. +48.5%). The company continues to post revenue growth, driven by higher volumes across all segments. Caterpillar returned to earnings growth in the fourth quarter of 2025 (albeit by a modest +0.4%) after five quarters of declines. This is a notable achievement given the ongoing tariff headwind. This is expected to persist into 2026, with management projecting a $2.6 billion impact.
A record backlog of $51.2 billion should support future sales. The Construction Industries segment stands to benefit from rising construction activity in the United States and globally, while Resource Industries will gain from steady commodity demand.
In Power & Energy, sustainability initiatives and data-center investments are driving demand. Caterpillar’s focus on building aftermarket parts and service-related revenues (which generate high margins) will aid growth.
(You can read the full research report on Caterpillar here >>>)
Shares of Texas Instruments have outperformed the Zacks Semiconductor - General industry over the past six months (+69.4% vs. +11.5%). The company is benefiting from solid data center demand, which is boosting its prospects in the enterprise systems market. A sustained focus on expanding its product portfolio across the Analog and Embedded Processing segments helps capture market share.
Texas Instruments’ deepening focus on internal manufacturing and advanced technology infusion is another positive. Its robust cash flows and aggressive shareholder return policies instill confidence in its long-term prospects.
However, its overall growth might be impacted by a slow recovery in the industrial market, as customers are cautiously spending amid ongoing macroeconomic uncertainties. Rising manufacturing costs and the growing tech war between the United States and China are other concerns.
(You can read the full research report on Texas Instruments here >>>)
Boeing’s shares have outperformed the Zacks Aerospace - Defense industry over the past six months (+5.8% vs. -7.8%). The company ended the first quarter of 2026 on a solid note, with its revenues and earnings having surpassed the respective Zacks Consensus Estimate. Boeing remains one of the largest U.S. commercial aircraft manufacturers.
Steadily growing commercial air travel should boost Boeing’s service business unit. The outlook for Boeing’s defense and space business segment also remains optimistic. Government’s inclination toward strengthening the nation’s defense and space system should act as a growth catalyst for Boeing.
However, Boeing faces risks related to the shortage of skilled labor. Trade tensions between the United States and China may cause Boeing to be unsuccessful in the timely delivery of its jets and thereby hurt its operational performance.
(You can read the full research report on Boeing here >>>)
Shares of Kewaunee Scientific have outperformed the Zacks Instruments - Scientific industry over the past year (+4.9% vs. -6.3%). This microcap company with a market capitalization of $103.51 million is strengthening its business mix through the Nu Aire integration, expanding beyond cyclical lab construction into recurring airflow and containment products, which helps stabilize utilization and earnings.
A solid backlog provides near-term revenue visibility despite normalization, while a growing international segment—led by India—and turnkey project capabilities enhance diversification, customer stickiness, and share of wallet. Ongoing reinvestment in systems and talent supports scalability and operational discipline.
However, domestic operations remain exposed to construction timing volatility, pressuring margins. Corporate costs continue to weigh on profitability during platform buildout, and liquidity has tightened amid debt servicing. Rising stock-based compensation also creates ongoing margin and EPS headwinds.
(You can read the full research report on Kewaunee Scientific here >>>)
Vaso’s shares have outperformed the Zacks Medical - Instruments industry over the past year (+45.7% vs. -0.8%). This microcap company with a market capitalization of $33.22 million has maintained a balance between structural stability and execution risk. Its diversified operating model and growing deferred revenue base support revenue visibility, while a long-term partnership provides continuity but also introduces customer concentration and dependence on delivery cycles.
The ongoing shift toward managed IT services and software-led solutions aligns with industry trends, though uneven execution and prior asset impairments reflect challenges in translating strategy into consistent earnings. Profitability remains constrained by a high-cost structure, limiting operating leverage.
Strong liquidity provides flexibility, but cash generation is still influenced by timing dynamics. The valuation suggests investor skepticism around earnings quality, scalability and Vaso’s ability to convert its positioning into durable returns.
(You can read the full research report on Vaso here >>>)
Other noteworthy reports we are featuring today include The Charles Schwab Corp. (SCHW), Amgen Inc. (AMGN) and CSX Corp. (CSX).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Schwab (SCHW) to Gain from Acquisitions, AI Push Amid Cost Pressures
Per the Zacks analyst, strategic buyouts, a rise in investing solution fees and leveraging AI to expand relationship-based business will aid Schwab, while elevated costs and pricing pressure are woes.
Amgen's (AMGN) Key Drugs Aid Growth Amid Biosimilar Competition
The Zacks analyst believes that Amgen's key drugs and newer medicines are driving sales, more than offsetting declining revenues from oncology biosimilars and legacy established products.
CSX (CSX) Benefits From Dividends and Buyback Amid High Debt
The Zacks analyst likes the shareholder-friendly measures adopted by CSX. However, high debt does not bode well for its bottom line.
Elevance's (ELV) Strategic Buyouts and Product Expansion Aid
Per the Zacks analyst, acquisitions, partnerships and product expansions are helping Elevance Health boost its portfolio, leading to steady revenue growth. Yet, rising costs are affecting profits.
United Rentals (URI) Gains on Specialty Growth Amid Margin Risk
Per the Zacks analyst, United Rentals benefits from large-project activity, Specialty strength and fleet productivity. However, margin variability tied to delivery, depreciation and mix temper upside.
Halliburton's (HAL) Strong Growth in Latin America Drives Gains
The Zacks analyst believes that Halliburton is capitalizing on strong activity in Latin America, but geopolitical conflicts in the Middle East may lead to a significant decline in earnings for Q2.
Viavi (VIAV) Rides on Healthy Demand Across Several Verticals
Per the Zacks analyst, strong demand across aerospace and defense, data centers, and cloud infrastructure is expected to drive Viavi's top line. The Spirent buyout has strengthened its portfolio.
New Upgrades
Casey's (CASY) Inside Sales Surge Highlights Omnichannel Strength
Per the Zacks analyst, Casey's strong omnichannel momentum is driving sustained growth in its core inside business, with management projecting inside same-store sales to rise 3.5%-4.5% in fiscal 2026.
DRAM and HBM Growth Continues to Aid Formfactor's (FORM) Prospects
Per the Zacks analysis, DRAM and HBM demand growth, rising test intensity, and HBM4 transition strength are expected to support FormFactor's margins and long-term prospects.
Strong Demand for Pega Cloud Aids Pegasystems (PEGA) Prospects
Per the Zacks analyst, Pegasystems is benefiting from strong revenues driven by robust demand for its AI-powered and cloud-based solutions
New Downgrades
Centrus Energy (LEU) Faces Risk from Funding, Expansion Costs
Per the Zacks analyst, a backlog contingent on capacity expansion and securing external funding as well as heavy spending can weigh on Centrus Energy's results.
Pilgrim's Pride (PPC) Faces Demand Shift and Competitive Pressures
Per the Zacks analyst, shifting consumer behavior and intense industry competition may pressure Pilgrim's Pride's sales volumes, pricing power and margins in a challenging demand environment.
Weak Demand and Margin Pressures Ail International Paper (IP)
The Zacks analyst is concerned that weak demand in end markets, along with higher maintenance outage expense will continue to impact International Paper's results.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Stock Reports for Caterpillar, Texas Instruments & Boeing

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Applied Materials, Inc. (Symbol: AMAT), where a total volume of 33,920 contracts has been traded thus far today, a contract volume which is representative of approximately 3.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60.1% of AMAT's average daily trading volume over the past month, of 5.6 million shares. Especially high volume was seen for the $432.50 strike call option expiring April 24, 2026, with 9,101 contracts trading so far today, representing approximately 910,100 underlying shares of AMAT. Below is a chart showing AMAT's trailing twelve month trading history, with the $432.50 strike highlighted in orange:
Amgen Inc (Symbol: AMGN) saw options trading volume of 14,101 contracts, representing approximately 1.4 million underlying shares or approximately 57.6% of AMGN's average daily trading volume over the past month, of 2.4 million shares. Particularly high volume was seen for the $295 strike call option expiring June 18, 2026, with 3,345 contracts trading so far today, representing approximately 334,500 underlying shares of AMGN. Below is a chart showing AMGN's trailing twelve month trading history, with the $295 strike highlighted in orange:
And Dominos Pizza Inc. (Symbol: DPZ) saw options trading volume of 4,453 contracts, representing approximately 445,300 underlying shares or approximately 54.5% of DPZ's average daily trading volume over the past month, of 817,040 shares. Particularly high volume was seen for the $390 strike call option expiring May 15, 2026, with 754 contracts trading so far today, representing approximately 75,400 underlying shares of DPZ. Below is a chart showing DPZ's trailing twelve month trading history, with the $390 strike highlighted in orange:
For the various different available expirations for AMAT options, AMGN options, or DPZ options, visit StockOptionsChannel.com.
Also see:
Low Priced Dividend Stocks
IPG Stock Predictions
Low Beta Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: AMAT, AMGN, DPZ

Johnson & Johnson JNJ, via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, pulmonary hypertension and infectious diseases.
J&J’s Innovative Medicine segment’s sales rose 7.4% on an operational basis
(excluding the impact of currency) to $15.43 billion in the first quarter of 2026. On an organic basis, sales rose 5.6% despite the loss of exclusivity (“LOE”) of the multi-billion-dollar product, Stelara. In the quarter, J&J’s 11 key brands delivered double-digit growth.
J&J’s Innovative Medicine Segment’s Q1 Performance
Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment’s growth. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. The sales growth was partially dampened by a steeper-than-expected decline in sales of Stelara due to biosimilar erosion and lower sales of Imbruvica.
Sales of blockbuster multiple myeloma treatment, Darzalex, rose 22.5% year over year to $3.96 billion in the quarter. Erleada generated sales of $949.0 million in the quarter, up 23.1% year over year, while Tremfya recorded sales of $1.61 billion in the quarter, up 68.3%.
Stelara’s sales declined 62% in the first quarter, which was steeper than expected. Stelara’s LOE negatively impacted the Innovative Medicines segment’s growth by 920 basis points and total revenues by 540 basis points in the first quarter.
J&J lost U.S. patent exclusivity of Stelara in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries, Samsung Bioepis/Sandoz and some other companies launched Stelara biosimilars in 2025.
J&J’s Innovative Medicine segment recorded four consecutive quarters of sales of more than $15 billion despite the LOE of Stelara.
J&J’s Innovative Medicine Segment’s Outlook for 2026 and Beyond
In 2026, J&J expects accelerated growth in the Innovative Medicine segment despite Stelara LOE. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato, Carvykti and Erleada, as well as increased contribution from new launches like Icotyde, Rybrevant and Inlexzo. J&J expects a more pronounced impact from new products in 2026 than in 2025.
However, as regards generic impact, in 2026, J&J expects the Stelara LOE impact to be more pronounced. In addition, J&J expects generic impact for both Simponi and Opsumit to begin in 2026 as the drugs lose patent protection.
J&J expects to generate $100 billion in revenues in 2026. It expects sales to continue to improve in 2027, with a “line of sight” to double-digit growth by the end of the decade. In fact, the company is already demonstrating this momentum—excluding Stelara, its total revenue grew at a double-digit rate in the first quarter.
Though J&J expects accelerated growth in both the Innovative Medicine and MedTech segments in 2026, the Innovative Medicine segment should be a critical franchise for driving company-wide top-line growth and profitability despite the Stelara LOE.
Overall, J&J’s Innovative Medicine segment remains resilient, with strong growth from key drugs and new launches offsetting Stelara’s LOE impact. Despite near-term biosimilar and patent headwinds, the segment is well-positioned to drive sustained long-term growth.
J&J Key Competitors
Immunology and oncology are J&J’s key areas. Other large drugmakers with a strong presence in the oncology market include Novartis, AstraZeneca AZN, AbbVie ABBV, Amgen, Merck, Bristol-Myers, Roche and Pfizer. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry over the past year. The stock has risen 43.4% in the past year compared with 17.5% appreciation of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 19.04 forward earnings, higher than 16.84 for the industry. The stock is also trading above its five-year mean of 15.65.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $11.54 to $11.57 over the past 30 days, while that for 2027 earnings has gone up from $12.44 per share to $12.57 over the same time frame.
Image Source: Zacks Investment Research
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?

Fintel reports that on April 21, 2026, Canaccord Genuity initiated coverage of Amgen (NasdaqGS:AMGN) with a Hold recommendation.
Analyst Price Forecast Suggests 4.64% Upside
As of April 15, 2026, the average one-year price target for Amgen is $360.85/share. The forecasts range from a low of $202.00 to a high of $453.60. The average price target represents an increase of 4.64% from its latest reported closing price of $344.86 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Amgen is 28,927MM, a decrease of 21.29%. The projected annual non-GAAP EPS is 23.09.
What is the Fund Sentiment?
There are 3,120 funds or institutions reporting positions in Amgen. This is an decrease of 877 owner(s) or 21.94% in the last quarter. Average portfolio weight of all funds dedicated to AMGN is 0.36%, an increase of 17.15%. Total shares owned by institutions decreased in the last three months by 12.86% to 436,436K shares. The put/call ratio of AMGN is 0.86, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 23,098K shares representing 4.28% ownership of the company. In its prior filing, the firm reported owning 18,795K shares , representing an increase of 18.63%. The firm increased its portfolio allocation in AMGN by 41.92% over the last quarter.
Capital International Investors holds 18,186K shares representing 3.37% ownership of the company. In its prior filing, the firm reported owning 19,193K shares , representing a decrease of 5.54%. The firm increased its portfolio allocation in AMGN by 6.75% over the last quarter.
Geode Capital Management holds 14,303K shares representing 2.65% ownership of the company. In its prior filing, the firm reported owning 13,268K shares , representing an increase of 7.24%. The firm increased its portfolio allocation in AMGN by 21.02% over the last quarter.
Charles Schwab Investment Management holds 11,811K shares representing 2.19% ownership of the company. In its prior filing, the firm reported owning 13,551K shares , representing a decrease of 14.73%. The firm decreased its portfolio allocation in AMGN by 1.60% over the last quarter.
Primecap Management holds 8,905K shares representing 1.65% ownership of the company. In its prior filing, the firm reported owning 9,708K shares , representing a decrease of 9.01%. The firm increased its portfolio allocation in AMGN by 5.15% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Canaccord Genuity Initiates Coverage of Amgen (AMGN) with Hold Recommendation

In early trading on Tuesday, shares of Zscaler topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.0%. Year to date, Zscaler has lost about 38.3% of its value.
And the worst performing Nasdaq 100 component thus far on the day is Alnylam Pharmaceuticals, trading down 2.9%. Alnylam Pharmaceuticals is lower by about 24.0% looking at the year to date performance.
Two other components making moves today are Amgen, trading down 2.1%, and Marvell Technology, trading up 2.8% on the day.
VIDEO: Nasdaq 100 Movers: ALNY, ZS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Nasdaq 100 Movers: ALNY, ZS

In early trading on Tuesday, shares of UnitedHealth Group topped the list of the day's best performing Dow Jones Industrial Average components, trading up 9.1%. Year to date, UnitedHealth Group registers a 6.9% gain.
And the worst performing Dow component thus far on the day is Amgen, trading down 2.1%. Amgen is showing a gain of 4.7% looking at the year to date performance.
Two other components making moves today are Merck, trading down 2.1%, and MMM, trading up 3.2% on the day.
VIDEO: Dow Movers: AMGN, UNH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	AMGN	Industry	AMGN	Industry	Volume, $
Yesterday 350.0 - 356.9	0.22	0.71	16.80	1.71	538.85M
Week 344.2 - 356.9	2.56	1.68	3.41	2.94	2.95B
Month 335.1 - 359.4	2.02	8.81	9.07	7.14	14.63B
3 Months 329.3 - 391.3	7.60	2.24	13.97	17.81	44.44B
6 Months 288.0 - 391.3	17.33	9.52	18.72	23.93	80.48B
Year 261.4 - 391.3	28.04	49.09	27.51	35.65	131.23B
3 years 211.7 - 391.3	45.83	6.33	44.66	75.29	283.59B
5 years 198.6 - 391.3	36.34	67.65	53.13	98.88	432.58B
All time 11.7 - 346.9	2,283.46	127.67	—	—	360.28B

Amgen Inc.

Price and volatility history

Risk ratios